



CIN: L51109PB2002PLC047444

Prism Medico And Pharmacy Limited

Reg. Office : D-118, Industrial Area, Phase VII, Mohali-160055

Tel: 0172-5020762

Email : investorgrievancewmcl@gmail.com

www.prismmedico.com

Date: 22/11/2021

To,
Department of Corporate Services,
BSE LIMITED
P. J. Towers, Dalal Street,
Mumbai - 400 001

Scrip Code: 512217

To,
Listing Department,
**Metropolitan Stock Exchange of India Ltd.
(MSE)**
Vibgyor Towers, 4th floor,
Plot No C 62, G - Block,
Opp. Trident Hotel,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 098, India.
ISIN : INE730E01016

Dear Sir / Madam,

SYMBOL: AJOONI

Sub: Reply to Observations to your e-mail dated 19th November 2021

Dear Sir,

This is with reference to your e-mail dated 19th November 2021 regarding Non-compliance with Regulation 33 of SEBI (LODR) Regulations, 2015 for quarter ended September 2021, kindly note that in this regard, quarterly and half year ended un-audited financial statements were submitted successfully by the company on 13/11/2021.

We regret to inform you that due to an inadvertent error cash flow statement in this regard was not attached. Further, we are attaching herewith Cash Flow Statement with un-audited results for half year ended 30th September 2021. You are requested to take the same on record and acknowledge.

Thanking You,

Yours Truly,

For PRISM MEDICO & PHARMACY LIMITED


Sameer Gupta
Company Secretary
A-59256




CIN: L51109PB2002PLC047444

Prism Medico And Pharmacy Limited

Reg. Office : D-118, Industrial Area, Phase VII, Mohali-160055

Tel: 0172-5020762

Email : investorgrievancewmcl@gmail.com

www.prismmedico.com

CASH FLOW STATEMENT 30.09.2021

Particulars	Period ended 30.09.2021 Amount
A. Cash Flow from Operating Activities:	
Profit before tax for the year	(1,533,551.00)
Adjustments for	
Depreciation & Amortization	45,748.00
Interest & Finance Charges	-
Operating Profit Before Prior Period Items and Working Capital Changes	(1,487,803.00)
Operating Profit Before Working Capital Changes	(1,487,803.00)
Adjustments for:	
Decrease/(Increase) in Receivables	112,400
Inventories	-
Other Current Assets	-
Other Current Liabilities	441,652
Increase/(Decrease) in Trade Payables	874,000
Cash Generated from Operations	(59,751)
Income Tax Paid	
Net Cash from Operating Activities	(59,751)
B. Cash Flow from Investing Activities:	
Investments	
Loans & Advances given	
Net Cash (used)/Generated in Investing Activities	-

C. Cash Flow from Financing Activities:

Proceed from Share Capital
Proceeds/(Repayment) of Long Term
Borrowings
Proceeds/(Repayment) of Short Term
Borrowings
Interest and Other Finance Costs paid

**Net Cash (Used)/Generated in Financing
Activities**

Net Increase in Cash and Cash Equivalents (A)+(B)+(C)

Opening Cash and Cash Equivalents

Closing Cash and Cash Equivalents

(59,751)

841,329

781,577

**FOR & ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LTD.**

Place : Mohali

Date: 13/11/2021


Ramandeep Singh
Whole time Director (DIN: 07896086)





CIN: L51109PB2002PLC047444

Prism Medico And Pharmacy Limited

Reg. Office : D-118, Industrial Area, Phase VII, Mohali-160055

Tel: 0172-5020762

Email : investorgrievancewmcl@gmail.com

www.prismmedico.com

Date: 13/11/2021

To,
Department of Corporate Services,
BSE LIMITED
P. J. Towers, Dalal Street,
Mumbai - 400 001

Scrip Code: 512217

To,
Listing Department,
**Metropolitan Stock Exchange of India Ltd.
(MSE)**
Vibgyor Towers, 4th floor,
Plot No C 62, G - Block,
Opp. Trident Hotel,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 098, India.
ISIN : INE730E01016

Dear Sir / Madam,

Sub.: Approval of Un-Audited Financial Results for the quarter and half year ended September 30, 2021.

Dear Sir,


Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on 13/11/2021 at the Registered Office of the company have considered and approved the un-audited Financial Results for the quarter and half year ended September 30, 2021. In this regards, we are enclosing herewith:

1. Un-audited Financial Results for the quarter and half year ended September 30, 2021.
2. Limited Review Report on Un-audited Financial Results for the quarter and half year ended September 30, 2021.

You are requested to kindly take the same on record.

Thanking You,
Yours Truly,

For **PRISM MEDICO & PHARMACY LIMITED**


Ramandeep Singh
Whole time Director
DIN: 07896086



PRISM MEDICO AND PHARMACY LTD.
CIN : L51109PB2002PLC047444

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2021 (IN LAKHS)

PARTICULARS	Quarter Ended (Unaudited)			Period Ended (UnAudited)	Period Ended (Unaudited)	Year Ended (Audited)
	30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
1 INCOME FROM OPERATIONS						
A Net Sales/ Income From Operations	0.00	0.00	637.77	0.00	637.77	1676.35
B Other Operating Income	0.00	0.00	0.00	0.00	0.00	
TOTAL INCOME FROM OPERATIONS (NET)	0.00	0.00	637.77	0.00	637.77	1676.35
2 EXPENSES:						
Cost of Material Consumed	0.00	0.00	597.98	0.00	597.98	2146.71
Change In Inventories	0.00	0.00	0.00	0.00	0.00	-479.90
Employee Benefit Expenses	8.44	0.00	0.42	8.44	0.42	16.76
Depreciation	0.23	0.23	0.31	0.46	0.61	1.23
Other expenses	1.21	5.22	1.35	6.43	5.96	9.04
TOTAL EXPENSES	9.88	5.45	600.06	15.33	604.97	1693.84
PROFIT / (LOSS) FROM OPERATION BEFORE OTHER INCOME, FINANCE COST AND EXCEPTIONAL ITEMS (1-2)	-9.88	-5.45	37.71	-15.33	32.80	-17.49
3 Other Income	0.00	0.00	0.00	0.00	0.00	0.00
PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE FINANCE COST AND EXCEPTIONAL ITEMS (3 + 4)	-9.88	-5.45	37.71	-15.33	32.80	-17.49
5 Finance Cost	0.00		0.00	0.00	0.00	0.02

7	PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER FINANCE COST BUT BEFORE EXCEPTIONAL ITEMS (5 + 6)	-9.88	-5.45	37.71	-15.33	32.80	-17.51
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9	PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (7 + 8)	-9.88	-5.45	37.71	-15.33	32.80	-17.51
10	TAX EXPENSE:						
	(1) Current Tax	0.00	0.00	9.80	0.00	9.80	0.00
	(2) Deferred Tax	0.0346	0.0346	0.0089		0.0200	4.51
	(3) MAT Credit	0.00	0.00	0.00	0.00	0.00	0.00
11	NET PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (9+10)	-9.91	-5.48	27.90	-15.33	22.98	-13.00
12	Extraordinary Items (Net of Tax ` Expense ____ Lakhs)	0.00	0.00	0.00	0.00	0.00	0.00
13	NET PROFIT / (LOSS) FOR THE PERIOD (11 + 12)	-9.91	-5.48	27.90	-15.33	22.98	-13.00
14	Share of Profit / (loss) of associates *	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority Interest *	0.00	0.00	0.00	0.00	0.00	0.00
16	NET PROFIT / (LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT / (LOSS) OF ASSOCIATES (13 + 14 + 15) *	-9.91	-5.48	27.90	-15.33	22.98	-13.00
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	606.34	606.34	606.34	606.34	606.34	606.34
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	670.85	680.77	722.21	670.85	722.21	686.25
19	Earnings Per Share (before extraordinary items) (of Rs ____/- each) (not annualised):						
	(1)BASIC	-0.02	-0.01	0.05	-0.03	0.04	-0.02
	(2)DILUTED	-0.02	-0.01	0.05	-0.03	0.04	-0.02
19	Earnings Per Share (after extraordinary items) (of Rs ____/- each) (not annualised):						

(1)BASIC	-0.02	-0.01	0.05	-0.03	0.04	-0.02
(2)DILUTED	-0.02	-0.01	0.05	-0.03	0.04	-0.02

* Applicable in the case of consolidated results.

Notes:

1. The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 13/11/2021.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2017.
3. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.

**FOR & ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LTD.**



Ramandeep Singh
Whole time Director (DIN: 07896086)

Place : Mohali

Date: 13/11/2021

PRISM MEDICO AND PHARMACY LTD.
CIN : L51109PB2002PLCO47444

STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS ON 30TH SEPTEMBER, 2021

PARTICULARS	30.09.2021	31.03.2021
I. ASSETS		
(1) Non - Current Assets		
(a) Property, Plant and Equipment	507,661	553,409
b) Financial Assets		
(1) Non-Current Investments	19,380,000	19,380,000
b) Deferred Tax Asset	581,214	588,128
(2) Current Assets		
(a) Inventories	48,466,240	48,466,240
b) Financial Assets		
(1) Cash & Cash Equivalent	781,577	841,329
(2) Short Term Loans and advances	10,115,337	10,115,337
(3) Trade Receivables	135,027,012	135,139,412
(c) Other Current Asset	336,741	336,741
TOTAL		
Rs.	215,195,782	215,420,596
II EQUITY AND LIABILITIES		
(1) Equity		
(a) Equity Share Capital	60,634,280	60,634,280
(b) Other Equity	67,084,697	68,625,164
(2) Current Liabilities		
a) Financial Liabilities		
(1) Trade Payables	85,312,878	84,438,878
(b) Other Current Liabilities	2,163,927	1,722,275
TOTAL		
Rs.	215,195,782	215,420,596

FOR & ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LTD.

Place : Mohali
Date: 13/11/2021


Ramandeep Singh
Whole time Director (DIN: 07896086)



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

Limited Review Report on Standalone Financial Results

To Board of Directors of M/s Prism Medico & Pharmacy Limited

We have reviewed the Standalone Un-Audited Financial Result of **M/s. Prism Medico And Pharmacy Ltd** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 30th September 2021 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Harjeet Parvesh & Co,
Chartered Accountants

CA Konica Mohali

M.No 54759

Date : 13.11.2021

UDIN : 21547459 AAAACX6907.

House No. 1122, Sector 71, Mohali

Mobile :096460-27023, 098120-27023 | E-mail : harjeetca@yahoo.com